脊髓转移的预后结果:转移的时间和表现很重要
Shan-Lun Tsao1, Chang-Wei Tsou1, Yu-Ting Pan2
1Department of Medical Education, National Taiwan University Hospital, Taipei, Taiwan.
The spine journal : official journal of the North American Spine Society
|September 21, 2025
概括
同步脊髓转移 (SSM) 发生在最初的癌症诊断时,而元慢性脊髓转移 (MSM) 发生在以后. SSM 患者表现出生存优势,建议为这种独特的临床实体量身定制的治疗方法.
科学领域:
- 在瘤学瘤学.
- 神经外科 神经外科
- 辐射疗法 辐射疗法
背景情况:
- 脊髓转移 (SM) 可以同步 (SSM) 或超时 (MSM) 与原发性癌症发生.
- 诊断MS的时间影响治疗的复杂性和患者的结果.
- 了解SSM和MSM之间的临床和预后差异对于优化患者管理至关重要.
研究的目的:
- 调查SSM和MSM之间的发病率,预后和原发性恶性瘤差异.
- 通过分析来自手术和/或放射治疗病例的数据来改善临床实践.
- 为了更好的患者分层,确定SSM和MSM的独特特征.
主要方法:
- 在2010年至2022年期间接受治疗的4269名脊髓转移成年患者的回顾性研究.
- SSM定义为在初始癌症诊断后31天内诊断的SM; 后来诊断的MSM.
- 分析包括生存结果 (卡普兰-梅尔,考克斯模型) 和原发性恶性瘤分布 (奇方形/费舍尔精确测试).
主要成果:
- SSM发生率为19.6%,其中MSM占80.4%.
- 与MSM (7.5个月;p<.001) 相比,SSM患者的平均存活时间明显更长 (17.4个月).
- 肺癌是SSM病例中最常见的原发性恶性瘤;SSM患者的预后更为有利 (HR=0.74;p<.001).
结论:
- 大约五分之一的MS病例是在初级瘤 (SSM) 之前被诊断出来的.
- SSM患者表现出不同的临床和预后形状,通常具有生存优势.
- 针对SSM的量身定制的治疗方法,考虑到它们的有利前景,可能会改善结果.
相关概念视频
02:07Tumor Progression
7.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.2K
01:21Cancer Survival Analysis
650
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
650